{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000550","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.311178+00:00","generated_at":"2026-06-04T15:59:43.734697+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Chromocell appoints Frank Knuettel as permanent CEO, removing interim status","bullets":["Frank Knuettel appointed permanent CEO effective March 13, 2024; previously interim CEO since July 2023.","Knuettel will continue as CFO, Treasurer, and Secretary of the company.","He has raised over $300M in capital and managed 15+ M&A transactions during his career.","Knuettel retains same compensation terms under existing amended consultant agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000550","json":"https://secwatch.observer/filing/0001753926-24-000550.json","markdown":"https://secwatch.observer/filing/0001753926-24-000550.md","text":"https://secwatch.observer/filing/0001753926-24-000550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000550/0001753926-24-000550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000550/g084130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:59:43.734697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8966bb455","claim":"Francis Knuettel II was appointed as Chief Executive Officer at Pelthos Therapeutics Inc..","evidence_excerpt":"The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000550/0001753926-24-000550-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}